Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 95
Filtrar
2.
Pediatr Dermatol ; 40(4): 655-656, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37283451

RESUMO

Data regarding the treatment of childhood granulomatous periorificial dermatitis (CGPD) using oral therapies are limited. This study included 31 Chinese children with CGPD treated with oral roxithromycin. After 12 weeks of treatment, 90.3% of the patients recovered, and there were no severe adverse effects. Our results suggest that oral roxithromycin is an effective and safe treatment for CGPD.


Assuntos
Dermatite Perioral , Úlceras Orais , Roxitromicina , Criança , Humanos , Dermatite Perioral/tratamento farmacológico , População do Leste Asiático , Granuloma , Úlceras Orais/tratamento farmacológico , Roxitromicina/uso terapêutico
4.
J Cosmet Dermatol ; 20(12): 3839-3848, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33751778

RESUMO

BACKGROUND AND AIMS: Perioral dermatitis is a common cutaneous condition characterized by acneiform facial eruptions often with an eczematous appearance. A granulomatous subtype exists in addition to the classic variant. While topical corticosteroids have been largely implicated in this condition, its etiology is not completely understood. METHODS: Using the keywords "corticosteroids," "dermatology," "fusobacteria," "perioral dermatitis," and "periorificial dermatitis," we searched the databases PubMed, MEDLINE, and EMBASE to find the relevant literature. Only articles in English were chosen. The level of evidence was evaluated and selected according to the highest level working our way downwards using the Oxford Centre of Evidence-Based Medicine 2011 guidance. RESULTS: This systematic review found the strongest evidence to support topical corticosteroid misuse as the principal causative factor in the pathogenesis of perioral dermatitis. CONCLUSION: In terms of treatment, further research is required to robustly investigate promising treatment options including tetracyclines, topical metronidazole, topical azelaic acid, adapalene gel, and oral isotretinoin.


Assuntos
Dermatite Perioral , Fármacos Dermatológicos , Antibacterianos/uso terapêutico , Dermatite Perioral/diagnóstico , Dermatite Perioral/tratamento farmacológico , Dermatite Perioral/etiologia , Fármacos Dermatológicos/uso terapêutico , Humanos , Isotretinoína , Metronidazol/uso terapêutico
5.
J Dermatol ; 48(3): 405-407, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33275294

RESUMO

Pediatric periorificial dermatitis is a papulopustular eruption found around the facial orifices in children. Although the treatment of the disease has been largely anecdotal and experience-based, studies have shown that topical calcineurin inhibitors, as well as other topical and oral antibiotics, such as metronidazole, can be effective treatment options. However, most of the studies with a sizable number of patients have been based on the Caucasian population. Herein, we evaluated the clinical efficacy of topical calcineurin inhibitors and topical/oral metronidazole in 24 Korean patients with pediatric periorificial dermatitis. The majority of the patients showed a complete response to treatment.


Assuntos
Dermatite Perioral , Exantema , Administração Tópica , Antibacterianos/uso terapêutico , Inibidores de Calcineurina/uso terapêutico , Criança , Dermatite Perioral/diagnóstico , Dermatite Perioral/tratamento farmacológico , Exantema/tratamento farmacológico , Humanos , Metronidazol
11.
J Cosmet Dermatol ; 19(6): 1409-1414, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31660683

RESUMO

BACKGROUND: Perioral dermatitis is a clinically distinctive reaction pattern of facial dermatitis, including redness, dryness, burning, pruritus and skin tightness. A gold standard treatment remains unclear. OBJECTIVES: Our study evaluates the clinical value of a skin care cream with the transient receptor potential vanilloid type 1 inhibitor 4-t-butylcyclohexanol in POD patients over 8 weeks. METHODS: This open, unblinded 8-week clinical trial included 48 patients. A skin care cream containing 4-t-butylcyclohexanol was applied over a period of 8 weeks. Standardized questionnaires were used at baseline, 4 and 8 weeks, for history documentation, objective and subjective severity scores, and quality of life assessments. Six different skin physiology parameters were assessed at all timepoints. RESULTS: The perioral dermatitis severity score decreased significantly during the treatment period. This was mirrored by significantly lower patients' subjective numerical rating score and an improved quality of life score. Transepidermal water loss, stratum corneum hydration and skin erythema improved significantly during the treatment period. CONCLUSION: This transient receptor potential vanilloid type 1 inhibitor-based skin care cream improved subjective and objective parameters of perioral dermatitis. Decreased transepidermal water loss values and increased stratum corneum hydration demonstrate a restored skin barrier function. Consequently, the topical inhibition of these receptors is a promising management option for POD.


Assuntos
Cicloexanóis/uso terapêutico , Dermatite Perioral/tratamento farmacológico , Creme para a Pele/uso terapêutico , Canais de Cátion TRPV/antagonistas & inibidores , Adulto , Idoso , Idoso de 80 Anos ou mais , Cicloexanóis/farmacologia , Dermatite Perioral/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Índice de Gravidade de Doença , Creme para a Pele/farmacologia , Resultado do Tratamento , Perda Insensível de Água/efeitos dos fármacos , Adulto Jovem
12.
Dermatol Online J ; 26(12)2020 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-33423420

RESUMO

Childhood granulomatous periorificial dermatitis (CGPD), considered a clinical variant of perioral dermatitis, typically affects prepubertal children of African descent. It is a condition of unknown etiology characterized by the presence of a monomorphic yellow-brown papular eruption limited to the perioral, perinasal, and periocular regions that histopathologically shows a granulomatous pattern. This disorder should be differentiated from other conditions as granulomatous rosacea, sarcoidosis, and lupus miliaris disseminatus faciei. We report a case of a 9-year-old boy who presented with flesh-colored perorificial papules on the face, evolving for two months. Upon treatment with topical tacrolimus for follicular eczema, an aggravation of the condition was observed. A skin biopsy confirmed the diagnosis of CGPD. Our patient was successfully treated with a combination of topical metronidazole and topical erythromycin.


Assuntos
Dermatite Perioral/patologia , Granuloma/patologia , Administração Tópica , Anti-Infecciosos/uso terapêutico , Biópsia , Criança , Dermatite Perioral/tratamento farmacológico , Quimioterapia Combinada , Eritromicina/uso terapêutico , Face/patologia , Granuloma/tratamento farmacológico , Humanos , Imunossupressores/efeitos adversos , Masculino , Metronidazol/uso terapêutico , Pele/patologia , Tacrolimo/efeitos adversos
13.
J Drugs Dermatol ; 18(9): 955, 2019 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-31524997

RESUMO

A 42-year-old male with skin type I and a history of rosacea and eczema presented with crusting, erythema, and pustules distributed on the left oral commissure. Angular cheilitis was diagnosed and regular petrolatum use recommended until resolution of the lesion. Eight days later, with no improvement in symptoms, fungal and bacterial cultures were performed which resulted in the growth of cutibacterium acnes, a variant of p. acnes.


Assuntos
Dermatite Perioral/tratamento farmacológico , Glucocorticoides/administração & dosagem , Granuloma/tratamento farmacológico , Adulto , Humanos , Injeções Intralesionais , Masculino , Resultado do Tratamento , Triancinolona/administração & dosagem
14.
Pediatr Dermatol ; 36(6): 980-981, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31468559

RESUMO

Granulomatous periorificial dermatitis is a clinical variant of periorificial dermatitis. We present the case of an 18-year-old girl with several reddish papular lesions in the perioral, perinasal, and periorbital regions unresponsive to conventional therapy. After 6 months of therapy with low-dose oral isotretinoin, the lesions fully remitted.


Assuntos
Dermatite Perioral/tratamento farmacológico , Fármacos Dermatológicos/uso terapêutico , Granuloma/tratamento farmacológico , Isotretinoína/uso terapêutico , Administração Oral , Adolescente , Dermatite Perioral/patologia , Relação Dose-Resposta a Droga , Feminino , Granuloma/patologia , Humanos
15.
Eur J Clin Microbiol Infect Dis ; 38(9): 1677-1685, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31152265

RESUMO

Atopic dermatitis (AD), a chronic relapsing inflammatory pruritic skin disorder with a unique pathophysiology, has a high incidence in the perioral zone among infants. This study aimed to analyze the association of skin microfloral dynamics with disease severity and treatment of AD in 0-1-year-old infants. Based on the eczema area and severity index, subjects were divided into five groups, i.e., mild, moderate, severe, and severe post-treatment, with a healthy control group, and bacterial density at the perioral lesion, disease severity, and treatment were assessed in 0-1-year-old infants with AD. The perioral lesions were colonized predominantly by Firmicutes, followed in abundance by Proteobacteria, Actinobacteria, and Bacteroidetes. In the phylum Firmicutes, Streptococcus was the most predominant genus. In AD infants, the abundance of Bacteroidetes and Fusobacterium decreased significantly with an increase in disease severity (p < 0.01). The abundance of 6 genera, including Prevotella, decreased significantly with an increase in disease severity (p < 0.05). The abundance of Prevotella melaninogenica decreased gradually with an increase in disease severity and increased after treatment; this trend was reversed for Corynebacterium simulans. A reduction in the abundance of Staphylococcus and an increase in that of skin microflora including Prevotella spp., Staphylococcus epidermidis, and Erwinia dispersa were associated with treatment and clinical improvement. Skin bacterial composition varies with AD severity, and Corynebacterium simulans and Prevotella melaninogenica are positively and negatively correlated with AD severity, respectively. This study provides a theoretical basis to identify potential biomarkers AD occurrence and pathogenesis.


Assuntos
Bactérias/efeitos dos fármacos , Dermatite Atópica/microbiologia , Dermatite Perioral/microbiologia , Microbiota , Pele/microbiologia , Bactérias/classificação , Dermatite Atópica/tratamento farmacológico , Dermatite Perioral/tratamento farmacológico , Eczema , Humanos , Lactente , Recém-Nascido , RNA Ribossômico 16S , Índice de Gravidade de Doença
16.
J Cutan Med Surg ; 23(4): 442-448, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31053034

RESUMO

Pimecrolimus is a topical calcineurin inhibitor currently approved for second-line use in the management of mild-to-moderate atopic dermatitis in patients age 2 years and older. Given the safety profile and nonsteroidal mechanism of pimecrolimus, there has been significant interest in its use in the treatment of a variety of dermatological conditions. This article reviews research that has been published on the off-label uses of topical pimecrolimus, with a focus on published RCTs. Convincing evidence exists supporting pimecrolimus' efficacy in oral lichen planus and seborrheic dermatitis. For other conditions studied to date, pimecrolimus may prove to be a useful treatment alternative when conventional agents fail. Adverse events seen with its off-label use were typically application site reactions, the most common being a transient burning sensation. In summary, pimecrolimus appears to be an effective agent in the treatment of multiple dermatological conditions and may be worth considering as a pharmacologic alternative in several conditions when first-line treatment fails, or for areas that are more susceptible to the adverse effects of topical corticosteroids.


Assuntos
Inibidores de Calcineurina/uso terapêutico , Dermatopatias/tratamento farmacológico , Tacrolimo/análogos & derivados , Administração Tópica , Inibidores de Calcineurina/administração & dosagem , Inibidores de Calcineurina/efeitos adversos , Dermatite Alérgica de Contato/tratamento farmacológico , Dermatite Perioral/tratamento farmacológico , Dermatite Seborreica/tratamento farmacológico , Dermatoses da Mão/tratamento farmacológico , Humanos , Líquen Plano Bucal/tratamento farmacológico , Uso Off-Label , Psoríase/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Rosácea/tratamento farmacológico , Tacrolimo/administração & dosagem , Tacrolimo/efeitos adversos , Tacrolimo/uso terapêutico , Vitiligo/tratamento farmacológico
18.
Dermatology ; 235(2): 137-143, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30463069

RESUMO

OBJECTIVES: Potassium iodide (KI) is a medication that has been used for decades in dermatology and it is mentioned as a treatment option in all major dermatology textbooks. Yet, there is little recent information on its efficacy. In our study, we wanted to retrospectively evaluate the therapy response to KI in our patients. METHODS: The hospital information system was searched for patients treated with KI at the Department of Dermatology (University Hospital Zurich) in the last 20 years (January 1, 1998 to December 31, 2017). A total of 52 patients were found and, subsequently, 35 patients were included in our study. RESULTS: KI was prescribed for the following skin conditions: erythema nodosum, disseminated granuloma anulare, necrobiosis lipoidica, nodular vasculitis, cutaneous sarcoidosis, and granulomatous perioral dermatitis/ rosacea. The median duration of KI intake was 5 ± 7.7 weeks (range 1-26). The global assessment of efficacy by the treating physician showed an improvement of disease in about a third of all patients. No response was seen in 14 patients and 9 even had a progression of disease. An adverse event was documented in 16 cases. CONCLUSIONS: Our findings show that an improvement was reached in only about a third of all cases. High response rates with only mild side effects (in 16 out of 35 patients) were observed.


Assuntos
Fármacos Dermatológicos/uso terapêutico , Iodeto de Potássio/uso terapêutico , Sarcoidose/tratamento farmacológico , Dermatopatias/tratamento farmacológico , Adolescente , Adulto , Idoso , Dermatite Perioral/tratamento farmacológico , Eritema Nodoso/tratamento farmacológico , Feminino , Granuloma Anular/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Necrobiose Lipoídica/tratamento farmacológico , Estudos Retrospectivos , Rosácea/tratamento farmacológico , Dermatopatias Vasculares/tratamento farmacológico , Vasculite/tratamento farmacológico , Adulto Jovem
19.
Rev. Paul. Pediatr. (Ed. Port., Online) ; 36(4): 511-514, out.-dez. 2018. graf
Artigo em Português | LILACS | ID: biblio-977087

RESUMO

RESUMO Objetivo: Apresentar um caso de dermatite perioral granulomatosa (DPG) com acometimento extrafacial e resposta terapêutica satisfatória ao uso de macrolídeo oral por curto período. Descrição do caso: Escolar de nove anos, sexo feminino, com quadro exuberante de DPG com acometimento extrafacial. Durante o período de evolução, submeteu-se a múltiplas terapêuticas ineficazes, apresentando melhora significativa das lesões após o uso de azitromicina por cinco dias. Comentários: A DPG é uma afecção dermatológica inflamatória representada por erupções papuloeritematosas em região perioral, nasal e periorbitária, mais comum em crianças e adolescentes. Raramente estende-se à região genital, ao tronco e às extremidades, caracterizando o comprometimento extrafacial. De etiologia ainda desconhecida, parece apresentar correlação com uso de corticosteroides tópicos e outros agentes.


ABSTRACT Objective: To present a case of granulomatous perioral dermatitis (GPD) with extra-facial involvement and good response to short-term treatment with oral macrolide. Case description: A 9-year-old girl presented with exuberant GPD with extra-facial involvement. During follow-up, she received multiple ineffective therapies, but showed significant improvement of the lesions after the use of azithromycin for five days. Comments: GPD is an inflammatory dermatological condition represented by papulo-erythematous eruptions on perioral, nasal and periorbital regions, more prevalent in children and adolescents. It rarely extends to the genital region, trunk, and extremities, which characterizes its extra-facial manifestation. Its etiology is unknown, but it seems to have a correlation with the use of topical corticosteroids and other agents.


Assuntos
Humanos , Feminino , Criança , Azitromicina/administração & dosagem , Antibacterianos/administração & dosagem , Indução de Remissão , Administração Oral , Dermatite Perioral/complicações , Dermatite Perioral/tratamento farmacológico , Granuloma/complicações , Granuloma/tratamento farmacológico
20.
Rev Paul Pediatr ; 36(4): 511-514, 2018.
Artigo em Português, Inglês | MEDLINE | ID: mdl-29995140

RESUMO

OBJECTIVE: To present a case of granulomatous perioral dermatitis (GPD) with extra-facial involvement and good response to short-term treatment with oral macrolide. CASE DESCRIPTION: A 9-year-old girl presented with exuberant GPD with extra-facial involvement. During follow-up, she received multiple ineffective therapies, but showed significant improvement of the lesions after the use of azithromycin for five days. COMMENTS: GPD is an inflammatory dermatological condition represented by papulo-erythematous eruptions on perioral, nasal and periorbital regions, more prevalent in children and adolescents. It rarely extends to the genital region, trunk, and extremities, which characterizes its extra-facial manifestation. Its etiology is unknown, but it seems to have a correlation with the use of topical corticosteroids and other agents.


OBJETIVO: Apresentar um caso de dermatite perioral granulomatosa (DPG) com acometimento extrafacial e resposta terapêutica satisfatória ao uso de macrolídeo oral por curto período. DESCRIÇÃO DO CASO: Escolar de nove anos, sexo feminino, com quadro exuberante de DPG com acometimento extrafacial. Durante o período de evolução, submeteu-se a múltiplas terapêuticas ineficazes, apresentando melhora significativa das lesões após o uso de azitromicina por cinco dias. COMENTÁRIOS: A DPG é uma afecção dermatológica inflamatória representada por erupções papuloeritematosas em região perioral, nasal e periorbitária, mais comum em crianças e adolescentes. Raramente estende-se à região genital, ao tronco e às extremidades, caracterizando o comprometimento extrafacial. De etiologia ainda desconhecida, parece apresentar correlação com uso de corticosteroides tópicos e outros agentes.


Assuntos
Antibacterianos/administração & dosagem , Azitromicina/administração & dosagem , Dermatite Perioral/tratamento farmacológico , Administração Oral , Criança , Dermatite Perioral/complicações , Feminino , Granuloma/complicações , Granuloma/tratamento farmacológico , Humanos , Indução de Remissão
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...